Skip to main content

NET not compulsory for PhD

The University Grants Commission (UGC) has amended two sets of its regulation. It has relaxed the minimum eligibility norms (NET) for the appointment of assistant professors and has granted more time for women and differently-abled scholars to complete their Ph.D and M.Phil degrees.

HRD Minister Smriti Irani announced these two new amendments in a press conference on  April 12. The idea behind these amendments is to grant lectureship to non-NET students and to promote the entry of more women and differently-abled students into the field of research.

NET not compulsory
Till now, according to the 2009 regulations, a candidates would have required at least a post-graduate or an MPhil degree along with a cleared NET or SET (State-level eligibility test) as minimum eligibility for appointment in colleges and universities as teachers and lecturers. But now, those who have completed a Ph.D or registered for a Ph.D before 2009 would be eligible for lectureship without clearing the NET, reported by The Huffington Post.

The decision has been taken keeping in mind the creation  of more job opportunities in teaching field.

However, a candidate should adhere to certain conditions to be exempted of NET.  The candidate’s Ph.D degree should be awarded in regular mode and the research thesis should have been evaluated by at least two external examiners. Also, the candidate should have appeared for viva-voce and have published at least two papers based on the Ph.D thesis in research journals.

Ph.D and M.Phil tenure relaxed
The UGC would now allow women and differently-abled students to complete their Ph.D in eight years instead of the present six years and M.Phil in three years instead of two years.

Women candidates will also be provided maternity and child care leave for up to 240 days in the entire duration of their M.Phil or Ph.D degrees, as reported by IndiaTVNews.

In case of relocation of a woman Ph.D or M.Phil scholar due to marriage or otherwise, her research data shall be allowed to be transferred to the university to which the scholar intends to relocate, though subject to certain norms.

The Logical Indian hopes the decisions taken by the UGC and HRD ministry turns out to be good in long run. Now we all have to wait and for the end results of this amendments.
 

Comments

Popular posts from this blog

Pharma Companies HR contact information

Dear viewers of my blog, I am happy to share the HR contact details of Pharmaceutical companies. Contact Details Of Pharma HRs : Zaydus cadila-Goa gajendravernekar@zayduscadila.com 09623458512/08326615143 Teva-Goa Maryann.Braganza@teva.co.in sanjay.pandit@teva.co.in 0832 6685538 Glenmark-Goa Vittal hebbalkar hr executivr - 9923476869 anupbannatti@glenmark-generics.com 09604151586 Watson-Goa Jyosna.bagule@watsonpharm.co.in runa.divkar@watsonpharm.co.in goa@watsonpharm.co.in 0832 6690666/777 Unichem Labs-Goa abhiram.panshikar@unichemlabs.com R&D  suraj.jadhav@unichemlabs.com vikas.parkar@unichemlabs.com Indico-Goa goahplc@Indoco.com varun.keny@indoco.com anand.ingole@Indoco.com 0832 6624109 Encube-Goa hr@encubeethicals.com nidhi.b@encubeethicals.com 8322392223 Torrent pharma-Ahmdabad mayurdesai@torrentpharma.com 9879603921/22/23/24 Emcure-pune RPKulkarni@emcure.co.in           Kishor.Mule@emcure.co.in Rahul.Morgaonkar@emcure.co.in recruitment@em

Novo Nordisk settles with 2 Florida venders of compounded (Semaglutide)Ozempic:

Novo Nordisk settles with 2 Florida venders of compounded Ozempic: Novo Nordisk has arrived at private settlements with two Florida merchants of intensified forms of the uber blockbuster semaglutide therapies Ozempic and Wegovy, the organization said on Friday. In June of last year, Novo recorded brand name encroachment claims against five dealers of knockoff renditions of the GLP-1 medications, which have seen soaring interest to battle weight reduction. Ekzotica Corp's. Restorative Laser Experts Drug Spa in Miami and Effinger Wellbeing's Nuvida Rx Weight reduction in Tallahassee are the initial two organizations to have settled their cases. As indicated by long-lasting directive orders, the dealers will quit utilizing Novo reserve and have consented to reveal for a considerable length of time that intensified variants of the medications have not gone through the security and viability norms expected by the FDA for supported drugs. "The litigants' unlawful showcasing

Hypertension-An Overview

INTRODUCTION: Systemic arterial hypertension is one of the strongest known modifiable risk factors for ischaemic heart disease, stroke, renal failure and heart failure. It remains poorly treated. As an asymptomatic disorder, people are understandably reluctant to accept adverse drug effects in addition to the inconvenience of long-term treatment. In this regard, modern drugs represent an enormous improvement. PATHOPHYSIOLOGY AND SITES OF DRUG ACTION Hypertension is occasionally secondary to some distinct disease. However, most patients with persistent arterial hypertension have essential hypertension. Arterial blood pressure is determined by cardiac output, peripheral vascular resistance and large artery compliance. Peripheral vascular resistance is determined by the diameter of resistance vessels (small muscular arteries and arterioles) in the various tissues. One or more of a ‘mosaic’ of interconnected predisposing factors (including positive family history, obesity and phys